Myasthenia Gravis

Mike Gilchrist
10/30/06
Overview

- Background
- Pathogenesis
- Clinical Manifestations
- Diagnosis
- Treatment
- Associated Conditions
Background

• “Severe muscle disease”
• Most common disorder of neuromuscular transmission
• Annual incidence of 10-20 new cases per million
• Prevalence 1 in 7500
• Age of onset has a bimodal distribution
  – Second and third decades (female predominance)
  – Sixth to eighth decade (male predominance)
Two Clinical Forms

• Ocular
  – Weakness limited to eyelids and extraocular muscles
  – Half of these patients have AChR antibodies

• Generalized
  – Also commonly affects ocular muscles
  – Bulbar, limb, and respiratory muscle involvement
  – Four-fifths of these patients have AChR antibodies
Pathogenesis

• In MG, underlying defect is a decrease in the number of available acetylcholine receptors (AChR) at postsynaptic muscle membrane

• Postsynaptic folds are flattened or “simplified”, causing less efficient neuromuscular transmission
BLOCKING AUTO-ANTIBODIES (Myasthenia gravis)

- Nerve
- Acetylcholine
- AChR
- Muscle cell
- Muscle activation

Muscle activation inhibited

Auto-antibody to AChR
Pathogenesis

• Autoimmune response mediated by anti-AChR antibodies
• Pathogenic antibodies are IgG and T cell dependent
• Thymus plays a role
  – Abnormal in 75% of pt’s with MG
  – Hyperplastic in 65%
  – Thymoma in 10%
Clinical Features

- Weakness and fatigability
- Cranial muscles, particularly eyelids and extraocular muscles, often involved early
- Diplopia and ptosis are common early complaints
- Weakness chewing (“I can’t chew meat”)
- Dysarthria
- Dysphagia
Clinical Features

- “Snarling” expression when patient attempts to smile (“myasthenia sneer”)
- Weakness becomes generalized in 85%
- Limb weakness is often proximal, may be asymmetric
- Respiratory muscle weakness (“myasthenic crisis”)
- Deep tendon reflexes and sensation are preserved
Diagnosis

- History and Physical
- “Tensilon Test”
- Repetitive Nerve Stimulation
- AChR antibody testing
- Single Fiber EMG
History and Physical

• Diplopia, ptosis
• Weakness in characteristic distribution
• Fatigability
• Reduced strength on exam
• Reduced vital capacity
Tensilon Test

- Edrophonium is an AChE inhibitor
- Rapid onset (30s) and short duration of action (about 5 minutes)
- Focus on a weak muscle group and evaluate for change
- Initial dose of 2mg given IV. If no change, give additional 8mg IV
- Beware cholinergic effects (nausea, diarrhea, salivation, fasiculations, bradycardia)
- Have atropine at bedside
Repetitive Nerve Stimulation

- Anti-AChE inhibitors stopped 6-24 hrs prior to testing
- 2-3 electric shocks/second delivered, action potentials recorded
- In normal individual, amplitude of evoked muscle action potential dose not change
- In pt with MG, rapid reduction in the amplitude of the evoked response of more than 10-15%
AChR Antibodies

- Presence diagnostic of MG, but a negative test does not exclude disease
- Measured level does NOT correspond well with severity of disease
- In an individual patient, however, treatment-induced fall in the antibody level often correlates with clinical improvement
Single Fiber EMG

- The most sensitive test for MG
- Electrode measures action potentials of two muscle fibers innervated by the same motor axon
- Variability in time of the 2nd action potential relative to the 1st is called “jitter”
- MG cause increased “jitter”
Treatment

- AChE inhibitors
  - Pyridostigmine (Mestinon)
- Immunosuppression
- Rapid immunomodulating treatments
  - Plasma exchange
  - IVIG
- Thymectomy
AChE inhibitors

- Pyridostigmine (Mestinon)
  - Effect starts in 15-30 minutes, lasts 3-4 hours
  - Titrate dosage to symptoms
  - Cholinergic symptoms can limit use
Plasmapheresis and IVIG

- **Plasmapheresis**
  - Pathogenic antibodies removed
  - Usually a course of 5 exchanges over a 2 week period
  - Useful for temporary relief of symptoms

- **IVIG**
  - Rapid improvement
  - 2g/kg typically administered over 5 days
Immunosuppression

- Glucocorticoids and cyclosporin generally produce improvement within 1-3 months
- Azathioprine and mycophenolate take up to a year to show effect
Thymectomy

- In the absence of tumor, 85% of patients have improvement after thymectomy
- Improvement takes months to years
Associated Conditions

- Disorders of the thymus
  - Thymoma
  - Hyperplasia of thymus
- Autoimmune disorders
  - Thyroiditis
  - Autoimmune thyroid disease (3-8%)
  - RA
  - SLE
- MG can be exacerbated by hyper/hypo thyroidism, occult infection, drugs
CT Scan of the Chest Obtained Four Years before Admission, Showing a Lobulated Anterior Mediastinal Mass (Arrow)

Sectioned Surface of the Thymic Tumor

Medullary Differentiation with a Hassall's Corpuscle (Arrow) (Hematoxylin and Eosin, x80)

Sources

• Harrison’s Principles of Internal Medicine, 15th Edition. 2001
• UptoDate. Myasthenia Gravis